Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Cancer Res. 2020 Nov 23;27(5):1476–1490. doi: 10.1158/1078-0432.CCR-20-2860

Figure 3.

Figure 3.

YM-254890 inhibits human UVM cell signaling and tumor growth. (A) IP1 accumulation assay in UVM cells and A375 cells (cutaneous BRAFV600E). Cells were treated with increasing concentrations of YM for 3 hours (left) and 24 hours (right). Data are expressed as IP1 concentration (nM) (mean ± SEM, n = 3) (B) Western blot analysis of indicated proteins in UVM cells and A375 cells treated with 500nM YM at 0, 2, 4, 8, and 24 hours. (C) Dose response of UVM and A375 cells treated with YM for 5 days at increasing dose and readout by CellTiter Glo 2.0. Data are expressed as the percentage RLU relative to that observed with vehicle. (mean ± SEM, n = 3). (D) Percent photon flux of OMM1.3 xenografts treated with vehicle or YM (2.5mg/kg) for 21 days (mean ± SEM, n = 10). Cells were transduced with pBMN for luciferase expression. Arrow indicates start of treatment at day 3. P < 0.05; *, P < 0.0005; ***, P < 0.0001, ****.